Support/SMA360°™ Patient Support

A circle of support for your patients*

The Biogen SMA360° support program provides services for patients and their
families that address nonmedical barriers to access to SPINRAZA.

The Biogen SMA360° support program provides services that include:

Logistics

Product education

Insurance benefits investigation

Financial assistance for eligible individuals

Download the Start Form to enroll your patient in the SMA360° support services. This form can also be used as a prescription†

Download the Start Form (English)

Download the Start Form (Spanish)

Dedicated support to help patients
with treatment logistics.

Once a Start Form has been submitted to Biogen, a dedicated Family Access Manager (FAM) will reach out to your patient to begin helping with the logistics surrounding treatment.

The FAM will help your patient whenever there is a question or concern related to nonmedical treatment logistics while on SPINRAZA. The FAM can provide information on SMA360° support services and how a caregiver or individual living with SMA may be eligible for programs tailored to their needs.

Questions about support
or treatment logistics?

Contact your Biogen Rare Disease Account Executive:

1-844-4SPINRAZA
(1-844-477-4672)

The Biogen Copay Program‡ can potentially cover both the SPINRAZA prescription and the treatment procedure

The SMA360° insurance and financial assistance programs are designed to help individuals with SMA and their families understand their insurance benefits for SPINRAZA, and find a feasible way to start treatment and continue as prescribed by their healthcare professional.

The Biogen Copay Program can help commercially insured patients lower their out-of-pocket costs to as low as $0 by potentially covering both the SPINRAZA prescription and the treatment procedure. A FAM is ready and able to educate patients and their families on the eligibility details of this program.

A child with later-onset SMA who is being treated with SPINRAZA

“Our family access manager is amazing. He has been with us almost since the beginning of Ashley’s SPINRAZA treatment.” —Antonia, mother of Ashley

It’s important to consider treating SMA as soon as possible1

Learn about disease progression
Start your patient on SPINRAZA

*SMA360° patient services from Biogen are available only to those who have been prescribed SPINRAZA. SMA360° is intended for US residents only.
†Depending on your method of procurement, the Start Form may be used as a prescription.
‡Depending on the individual’s income or, in some cases, if his/her medication is obtained from an out-of-network provider, there may be an annual cap that limits the amount of assistance they can receive over 1 year. Federal and state laws and other factors may prevent or otherwise restrict eligibility. Individuals covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. The Biogen Copay Program is only available once a claim has been submitted to and paid for by the insurance company. Individuals may remain enrolled in the Biogen Copay Program for as long as eligibility criteria are met. Contact an LCM for full eligibility requirements.

INDICATION

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. Patients may be at increased risk of bleeding complications.

In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 24 of 146 SPINRAZA-treated patients (16%) with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 sham-controlled patients (14%). Two SPINRAZA-treated patients developed platelet counts <50,000 cells per microliter, with the lowest level of 10,000 cells per microliter recorded on study day 28.

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. SPINRAZA is present in and excreted by the kidney. In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 71 of 123 SPINRAZA-treated patients (58%) had elevated urine protein, compared to 22 of 65 sham-controlled patients (34%).

Laboratory testing and monitoring to assess safety should be conducted. Perform a platelet count, coagulation laboratory testing, and quantitative spot urine protein testing at baseline and prior to each dose of SPINRAZA and as clinically needed.

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

SPINRAZA may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of SPINRAZA on growth would be reversible with cessation of treatment.

The most common adverse reactions (≥20% of SPINRAZA-treated patients and ≥5% more frequently than in control patients) that occurred in the infantile-onset controlled study were lower respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients (18%) than in control patients (10%). Because patients in this controlled study were infants, adverse reactions that are verbally reported could not be assessed. The most common adverse reactions that occurred in the later-onset controlled study were pyrexia, headache, vomiting, and back pain. Post-lumbar puncture syndrome has also been observed after the administration of SPINRAZA.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

Reference

1. Wadman RI, Wijngaarde CA, Stam M, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol. 2018;25(3):512-518.

Stay Connected
Sign up with us to receive the latest news, support information, and upcoming events.

ABOUT SMA
What Is SMA Multidisciplinary Care
Why SPINRAZA
About SPINRAZA How SPINRAZA Works Presymptomatic Efficacy Early-Onset Efficacy Later-Onset Efficacy Real-World Evidence Safety
Starting SPINRAZA
How to Start Find a Treatment Center Dosing & Administration
Patients on Therapy
Patients on Therapy
Support
Access & Reimbursement SMA360°™ Patient Support Events

©2024 Biogen. All rights reserved.
This site is intended for US Healthcare Professionals only.
SPZ-US-3383 v10 05/24